There is an especially urgent need for blood donors with type O blood and for platelet donors.
Although 6 active ingredients of sunscreen surpass the FDA threshold, findings of the study do not recommend discontinuing sunscreen use.
During a routine physical examination, a clinician suspects May-Hegglin anomaly because of the patient’s low platelet count and hearing loss.
Monoferric will be supplied in 100mg/mL, 500mg/5mL, and 1000mg/10mL single-dose vials for intravenous infusion after dilution.
Ongoing active bleeding should be treated with nasal packing; patients should be educated on packing.
Currently available blood biomarkers are not ready to replace clinical signs and symptoms in the diagnosis of transient ischemic attack.
Increases in capillary density, functional exchange surface seen in microvasculature of skeletal muscle.
In patients with type 2 diabetes mellitus, anemia is associated with the development of diabetic retinopathy.
Odds for ASD, ADHD, intellectual disability increased with anemia diagnosed during first 30 weeks.
Prevalence of all severities of hemophilia A and hemophilia B estimated at 17.1 and 3.8 cases per 100,000.
Partial response or better observed in 26% of patients receiving oral selinexor-dexamethasone.
Chimeric antigen receptor T-cell therapy boosts a patient’s own immune cells.
Risk for death higher even with depression remission vs never experiencing depression.
The World Health Organization (WHO) has updated the WHO Model List of Essential Medicines for 2019.
Severe fatigue was more common in NHL survivors compared with the general population.
Fewer individuals in voxelotor group versus placebo group have worsened anemia at week 24.
Findings seen for red blood cells from female, previously pregnant, or sex-discordant donors.
Hemolytic anemia and immune thrombocytopenic purpura were the most common complications of immune checkpoint inhibitor therapy.
For both type 1 and type 2 von Willebrand disease, higher BMI was associated with increased VWF:Ag and FVIII:C levels.
Researchers evaluated response rates to azacitidine and decitabine in patients with chronic myelomonocytic leukemia according to various sets of response criteria.